Skip to main content

Advertisement

Log in

The Impact of Nodal Dissection on Staging in Adrenocortical Carcinoma

  • Endocrine Tumors
  • Published:
Annals of Surgical Oncology Aims and scope Submit manuscript

Abstract

Background

The role of lymphadenectomy in adrenocortical carcinoma (ACC) is controversial, and formal lymph node (LN) dissection is not routine. We sought to determine the minimum number of LNs that must be examined to accurately identify a patient as node negative.

Methods

The National Cancer Database was used to identify patients diagnosed with ACC from 2004 to 2013 who underwent surgical resection. Patients with distant metastases, multivisceral resection, or missing surgical or lymphadenectomy data were excluded. The primary outcome was overall survival (OS).

Results

LNs were identified on histopathology in 156 patients. Of these, 35 (22%) had at least one positive LN. Positive LNs were associated with positive surgical margins (odds ratio [OR] 5.80, p = 0.002) and increasing LN yield (OR 1.06, p = 0.02). Overall, on Cox regression analysis, LN positivity (hazard ratio [HR] 3.02, p < 0.001) and positive surgical margins (HR 2.06, p = 0.048) independently predicted poor OS after controlling for other factors that may influence survival. LN(−) disease in patients with one to three LNs examined had poorer overall survival compared with when at least four LNs were examined (p = 0.02). None of the other patient, tumor, and treatment variables had any impact on OS of the LN(−) cohort. The likelihood of identifying nodal involvement was higher on examination of at least four LNs compared with examination of one to three LNs (30 vs. 16%, p = 0.03).

Conclusions

LN positivity in ACC tumors independently predicts worse 5-year OS and a minimum of four LNs may be required to accurately determine LN negativity.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Fig. 1

Similar content being viewed by others

References

  1. Kerkhofs TMA, Verhoeven RHA, Van der Zwan JM, et al. Adrenocortical carcinoma: a population-based study on incidence and survival in the Netherlands since 1993. Eur J Cancer. 2013;49(11):2579–86. doi:10.1016/j.ejca.2013.02.034.

    Article  PubMed  Google Scholar 

  2. Allolio B, Fassnacht M. Clinical review: adrenocortical carcinoma: clinical update. J Clin Endocrinol Metab. 2006;91(6):2027–37. doi:10.1210/jc.2005-2639.

    Article  CAS  PubMed  Google Scholar 

  3. Kerkhofs TMA, Verhoeven RHA, Bonjer HJ, et al. Surgery for adrenocortical carcinoma in The Netherlands: analysis of the national cancer registry data. Eur J Endocrinol. 2013;169(1):83–89. doi:10.1530/EJE-13-0142.

    Article  CAS  PubMed  Google Scholar 

  4. Lughezzani G, Sun M, Perrotte P, et al. The European Network for the Study of Adrenal Tumors staging system is prognostically superior to the international union against cancer-staging system: a North American validation. Eur J Cancer. 2010;46(4):713–19. doi:10.1016/j.ejca.2009.12.007.

    Article  PubMed  Google Scholar 

  5. Fassnacht M, Johanssen S, Quinkler M, et al. Limited prognostic value of the 2004 International Union Against Cancer staging classification for adrenocortical carcinoma: proposal for a Revised TNM Classification. Cancer. 2009;115(2):243–50. doi:10.1002/cncr.24030.

    Article  PubMed  Google Scholar 

  6. Reibetanz J, Jurowich C, Erdogan I, et al. Impact of lymphadenectomy on the oncologic outcome of patients with adrenocortical carcinoma. Ann Surg. 2012;255(2):363–69. doi:10.1097/SLA.0b013e3182367ac3.

    Article  PubMed  Google Scholar 

  7. Gerry JM, Tran TB, Postlewait LM, et al. Lymphadenectomy for adrenocortical carcinoma: is there a therapeutic benefit? Ann Surg Oncol. 2016;23(Suppl 5):708–13. doi:10.1245/s10434-016-5536-1.

    Article  PubMed  PubMed Central  Google Scholar 

  8. Saade N, Sadler C, Goldfarb M. Impact of regional Lymph Node dissection on disease specific survival in adrenal cortical carcinoma. Horm Metab Res. 2015;47(11):820–25. doi:10.1055/s-0035-1549877.

    Article  CAS  PubMed  Google Scholar 

  9. Nilubol N, Patel D, Kebebew E. Does lymphadenectomy improve survival in patients with adrenocortical carcinoma? a population-based study. World J Surg. 2016;40(3):697–705. doi:10.1007/s00268-015-3283-2.

    Article  PubMed  Google Scholar 

  10. Cianchi F, Palomba A, Boddi V, et al. Lymph Node recovery from colorectal tumor specimens: recommendation for a minimum number of lymph nodes to be examined. World J Surg. 2002;26(3):384–89. doi:10.1007/s00268-001-0236-8.

    Article  PubMed  Google Scholar 

  11. Watanabe S, Asamura H. Lymph Node dissection for lung cancer: significance, strategy, and technique. J Thorac Oncol. 2009;4(5):652–57. doi:10.1097/JTO.0b013e31819cce50.

    Article  PubMed  Google Scholar 

  12. Chen SL, Bilchik AJ. More extensive nodal dissection improves survival for stages I to III of colon cancer: a population-based study. Ann Surg. 2006;244(4):602–10. doi:10.1097/01.sla.0000237655.11717.50.

    PubMed  PubMed Central  Google Scholar 

  13. Bilimoria KY, Stewart AK, Winchester DP, Ko CY. The National Cancer Data Base: a powerful initiative to improve cancer care in the United States. Ann Surg Oncol. 2008;15(3):683–90. doi:10.1245/s10434-007-9747-3.

    Article  PubMed  PubMed Central  Google Scholar 

  14. Ecker BL, McMillan MT, Datta J, et al. Lymph node evaluation and survival after curative-intent resection of duodenal adenocarcinoma: a matched cohort study. Eur J Cancer. 2016;69:135–41. doi:10.1016/j.ejca.2016.09.027.

    Article  CAS  PubMed  Google Scholar 

  15. Bilimoria KY, Shen WT, Elaraj D, et al. Adrenocortical carcinoma in the United States: treatment utilization and prognostic factors. Cancer. 2008;113(11):3130–36. doi:10.1002/cncr.23886.

    Article  PubMed  Google Scholar 

  16. Fassnacht M, Allolio B. What is the best approach to an apparently nonmetastatic adrenocortical carcinoma? Clin Endocrinol (Oxf). 2010;73(5):561–65. doi:10.1111/j.1365-2265.2010.03867.x.

    Article  CAS  Google Scholar 

  17. Pommier RF, Brennan MF. An 11-year experience with adrenocortical carcinoma. Surgery. 1992;112(6):963–70; discussion 970.

    CAS  PubMed  Google Scholar 

  18. Mihai R. Diagnosis, treatment and outcome of adrenocortical cancer. Br J Surg. 2015;102(4):291–306. doi:10.1002/bjs.9743.

    Article  CAS  PubMed  Google Scholar 

  19. Polat B, Fassnacht M, Pfreundner L, et al. Radiotherapy in adrenocortical carcinoma. Cancer. 2009;115(13):2816–23. doi:10.1002/cncr.24331.

    Article  PubMed  Google Scholar 

  20. Adiuvo | EPICLIN. https://www.epiclin.it/adiuvo. Accessed 25 March 2017.

  21. Goldstein NS. Lymph node recoveries from 2427 pt3 colorectal resection specimens spanning 45 years. Am J Surg Pathol. 2002;26(2):179–89. doi:10.1097/00000478-200202000-00004.

    Article  PubMed  Google Scholar 

  22. Maurel J, Launoy G, Grosclaude P, et al. Lymph node harvest reporting in patients with carcinoma of the large bowel: a French population-based study. Cancer. 1998;82(8):1482–86.

    Article  CAS  PubMed  Google Scholar 

  23. Grubbs EG, Callender GG, Xing Y, et al. Recurrence of adrenal cortical carcinoma following resection: surgery alone can achieve results equal to surgery plus mitotane. Ann Surg Oncol. 2010;17(1):263–70. doi:10.1245/s10434-009-0716-x.

    Article  PubMed  Google Scholar 

  24. Terzolo M, Angeli A, Fassnacht M, et al. Adjuvant mitotane treatment for adrenocortical carcinoma. N Engl J Med. 2007;356(23):2372–80. doi:10.1056/NEJMoa063360.

    Article  CAS  PubMed  Google Scholar 

  25. Beuschlein F, Weigel J, Saeger W, et al. Major prognostic role of Ki67 in localized adrenocortical carcinoma after complete resection. J Clin Endocrinol Metab. 2015;100(3):841–49. doi:10.1210/jc.2014-3182.

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgment

None.

Disclosure

The CoC’s NCDB and the hospitals participating in the CoC NCDB are the source of the de-identified data used. They have not verified and are not responsible for the statistical validity of the data analysis or the conclusions derived by the authors.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Rasa Zarnegar MD.

Electronic supplementary material

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Panjwani, S., Moore, M.D., Gray, K.D. et al. The Impact of Nodal Dissection on Staging in Adrenocortical Carcinoma. Ann Surg Oncol 24, 3617–3623 (2017). https://doi.org/10.1245/s10434-017-6064-3

Download citation

  • Received:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1245/s10434-017-6064-3

Keywords

Navigation